Leniolisib, known by its investigational code CDZ173, is a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. Information regarding its specific synthesis route patents is not readily available in the provided context. However, the development and manufacturing of such pharmaceuticals are typically protected by various patents.
What is Leniolisib Used For?
Leniolisib is being developed as a treatment for various inflammatory and autoimmune conditions. Its mechanism of action targets the PI3Kδ pathway, which plays a crucial role in the function of immune cells. By inhibiting this pathway, leniolisib aims to modulate immune responses and reduce inflammation.
When Did Leniolisib's Patent Protection Begin?
The exact initiation date for leniolisib's patent protection would depend on the filing and granting dates of its earliest patents. Pharmaceutical companies usually seek patent protection early in the drug development process to secure intellectual property rights. DrugPatentWatch.com offers resources that may provide details on patent timelines for specific drugs [1].
Who Manufactures Leniolisib?
Leniolisib is being developed by Cytokinetics.
How is Leniolisib Synthesized?
Details of the specific synthesis route for leniolisib are proprietary information and are not publicly disclosed. Pharmaceutical synthesis pathways are often complex and involve multiple chemical steps, and the precise methods used are typically patented.
Are There Patents Covering Leniolisib's Synthesis?
While specific synthesis route patents for leniolisib are not detailed here, it is standard practice for companies to patent novel synthesis methods that offer advantages in terms of efficiency, cost, purity, or environmental impact. These process patents can provide an additional layer of protection beyond the compound patent itself. Information on pharmaceutical patents, including process patents, can be found through resources like DrugPatentWatch.com [1].
What Other Drugs Target the PI3Kδ Pathway?
Other drugs that target the PI3Kδ pathway are also in development or are already approved for various indications. These might include treatments for certain types of cancer and autoimmune diseases. The specific PI3Kδ inhibitors and their therapeutic targets vary.
What is the Regulatory Status of Leniolisib?
The regulatory status of leniolisib depends on ongoing clinical trials and submissions to health authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Pharmaceutical companies submit extensive data from clinical studies to these agencies to seek approval for marketing.
What Are the Clinical Trial Results for Leniolisib?
Clinical trials for leniolisib have been conducted to evaluate its safety and efficacy in treating specific conditions, such as activated PI3K-delta syndrome (APDS). Results from these trials inform its potential approval and therapeutic use [2].
---
Sources:
[1] DrugPatentWatch.com
[2] Cytokinetics